Global Pharmaceutical Contract Manufacturing Market 2016-2020

  • ID: 3957512
  • Report
  • Region: Global
  • 81 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5
Why the Pharmaceutical industry Will Continue to Rely On Contract Manufacturing

FEATURED COMPANIES

  • Abbott
  • Baxter
  • Cipla
  • Fareva
  • Lupin
  • Par Pharmaceutical
  • MORE
About Pharmaceutical Contract Manufacturing

Contract manufacturing involves outsourcing manufacturing products to organizations, which helps the organizations offer the same services at a relatively lower cost. Typically, in the pharmaceutical and biotechnology sectors, the sourcing companies seek contract manufacturing services to restructure their resource deployment toward high skill areas such as R&D and marketing. Contract manufacturing has potential growth opportunities in emerging countries such as India and China.

The analysts forecast the global pharmaceutical contract manufacturing market to grow at a CAGR of 6.91% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global pharmaceutical contract manufacturing market for 2016-2020. To calculate the market size, the report considers the revenue generated from various pharmaceutical drug manufacturing outsourcing activities.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Pharmaceutical Contract Manufacturing Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Catalent
- Lonza
- Pfizer CentreOne

Other prominent vendors
- Abbott
- Aenova
- Amgen
- Apotex
- Aspen
- AstraZeneca
- Aurobindo Pharma
- Baxter
- BERLIN-CHEMIE
- Biocon
- Biogen
- Boehringer Ingelheim
- Celltrion
- Cipla
- Coherus Biosciences
- Daiichi Sankyo
- Dr. Reddy's Laboratories
- Eli Lilly
- Emcure Pharmaceuticals
- Eurofarma Laboratories
- Fareva
- Gedeon Richter
- Gilead Sciences
- GlaxoSmithKline (GSK)
- Hospira
- Impax Laboratories
- Intas Pharmaceuticals
- Janssen Pharmaceuticals
- Lupin
- Merck
- Mitsubishi Tanabe Pharma
- Momenta Pharmaceuticals
- Natco Pharma
- Nexus Pharmaceuticals
- Novo Nordisk
- Orchid Chemicals & Pharmaceuticals
- Par Pharmaceutical
- Parenteral Drugs India
- Patheon
- Piramal
- Roche Holding
- Sanofi
- Synthon
- Teva Pharmaceuticals
- Valeant Pharmaceuticals
- Zentiva
- Zhejiang Huahai Pharmaceutical
- Zydus Cadila

Market drivers
- High number of US FDA-approved manufacturing facilities in emerging countries.
- For a full, detailed list, view the full report

Market challenges
- Capacity utilization issues and lack of information integration.
- For a full, detailed list, view the full report

Market trends
- Huge demand for next-generation biologics.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott
  • Baxter
  • Cipla
  • Fareva
  • Lupin
  • Par Pharmaceutical
  • MORE
Part 01: Executive summary
  • Highlights
Part 02: Scope of the report
  • Market overview
  • Top-vendor offerings
Part 03: Market research methodology
  • Research methodology
  • Economic indicators
Part 04: Introduction
  • Key market highlights
Part 05: Pharmaceutical manufacturing outsourcing
  • Increased regulatory guidelines coupled with healthcare cost containment efforts
  • Rapid innovation and reduced product development lifecycle
  • High capital investment
Part 06: Market landscape
  • Market overview
  • Five forces analysis
Part 07: Market segmentation by type of contract manufacturing
  • Global API/bulk drug contract manufacturing market
  • Global FDF market
Part 08: Geographical segmentation
  • Global pharmaceutical contract manufacturing market by geography
  • Pharmaceutical contract manufacturing market in Americas
  • Pharmaceutical contract manufacturing market in APAC
  • Pharmaceutical contract manufacturing market in EMEA
Part 09: Key leading countries

Part 10: Market drivers
  • Increased focus on core competence
  • High number of US FDA-approved manufacturing facilities in emerging countries
  • Shorter time-to-market
Part 11: Impact of drivers

Part 12: Market challenges
  • Capacity utilization issues and lack of information integration
  • Growing global competition
  • Lack of manufacturing standardization
Part 13: Impact of drivers and challenges

Part 14: Market trends
  • Consolidation through vertical integration, alliances, and acquisitions
  • Huge demand for next-generation biologics
  • Value-added services
Part 15: Vendor landscape
  • Competitive scenario
Part 16: Key vendor analysis
  • Catalent
  • Lonza
  • Pfizer CentreOne
  • Other prominent vendors
Part 17: Appendix
  • List of abbreviations
Part 18: About the Author

List of Exhibits

Exhibit 01: Service offerings
Exhibit 02: Overview of global pharmaceutical contract manufacturing market
Exhibit 03: Global pharmaceutical contract manufacturing market: Present and future scenario
Exhibit 04: Process of drug development
Exhibit 05: Value chain of pharmaceutical industry
Exhibit 06: Contract manufacturing market: Benefit analysis
Exhibit 07: Factors affecting pharmaceutical manufacturing outsourcing
Exhibit 08: Key factors and its impact on selection of CMOs
Exhibit 09: Global pharmaceutical contract manufacturing market: Market overview
Exhibit 10: CMO market growth
Exhibit 11: Overview of outsourced new drug abbreviations (NDAs) in CMO industry
Exhibit 12: Cost comparison of drug development in the US and India
Exhibit 13: Global pharmaceutical contract manufacturing market 2015-2020 ($ billions)
Exhibit 14: Average number of services outsourced by company type 2013-2015
Exhibit 15: Preference for choosing pharmaceutical outsourcing Partners
Exhibit 16: Factors affecting the global pharmaceutical contract manufacturing market
Exhibit 17: Opportunities analysis: Global pharmaceutical contract manufacturing market
Exhibit 18: Growth of global pharmaceutical contract manufacturing market 2016-2020
Exhibit 19: Five forces analysis
Exhibit 20: Market segmentation based on type of contract manufacturing
Exhibit 21: Segment outlook
Exhibit 22: Market overview of global API/bulk drug manufacturing market
Exhibit 23: Global API/bulk drug contract manufacturing market 2015-2020 ($ billions)
Exhibit 24: Global API/bulk drug contract manufacturing market
Exhibit 25: Overview of API outsourcing manufacturing market
Exhibit 26: Market share of global FDF market 2015
Exhibit 27: Types of dosage forms
Exhibit 28: Lifecycle analysis of dosage formulations
Exhibit 29: Global FDF market 2015-2020 ($ billions)
Exhibit 30: Market share of global pharmaceutical contract manufacturing market 2015
Exhibit 31: Global pharmaceutical contract manufacturing market: Geography outlook 2015-2020
Exhibit 32: Global pharmaceutical contract manufacturing market: Current and future impact
Exhibit 33: Pharmaceutical contract manufacturing market in Americas 2015-2020 ($ billions)
Exhibit 34: Pharmaceutical contract manufacturing market in APAC 2015-2020 ($ billions)
Exhibit 35: Pharmaceutical contract manufacturing market in EMEA 2015-2020 ($ billions)
Exhibit 36: Key leading countries
Exhibit 37: Impact of drivers and challenges on global pharmaceutical contract manufacturing market
Exhibit 38: Competitive advantage
Exhibit 39: Examples of global pharmaceutical companies sourcing from CMOs
Exhibit 40: Impact of drivers
Exhibit 41: Capacity constraints by stage production 2015
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Impact of trends on global pharmaceutical contract manufacturing market
Exhibit 44: Major M&A in global pharmaceutical contract manufacturing market
Exhibit 45: Key vendors: Geographical presence 2015
Exhibit 46: Catalent: Profile
Exhibit 47: Catalent: Metrics analysis
Exhibit 48: Catalent: Growth strategy matrix
Exhibit 49: Catalent: Opportunity assessment
Exhibit 50: Lonza: Profile
Exhibit 51: Lonza: Metrics analysis
Exhibit 52: Lonza: Growth strategy matrix
Exhibit 53: Lonza: Opportunity assessment
Exhibit 54: Pfizer CentreOne: Profile
Exhibit 55: Pfizer CentreOne profile: Metrics analysis
Exhibit 56: Pfizer CentreOne: Growth strategy matrix
Exhibit 57: Pfizer CentreOne: Growth opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott
  • Baxter
  • Cipla
  • Fareva
  • Lupin
  • Par Pharmaceutical
  • MORE
New Report Released: - Global Pharmaceutical Contract Manufacturing Market 2016-2020

The author of the report recognizes the following companies as the key players in the global pharmaceutical contract manufacturing market: Catalent, Lonza, and Pfizer CentreOne.

Other prominent vendors in the market are: Abbott, Aenova, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, BERLIN-CHEMIE, Biocon, Biogen, Boehringer Ingelheim, Celltrion, Cipla, Coherus Biosciences, Daiichi Sankyo, Dr. Reddy's Laboratories, Eli Lilly, Emcure Pharmaceuticals, Eurofarma Laboratories, Fareva, Gedeon Richter, Gilead Sciences, GlaxoSmithKline (GSK),Hospira, Impax Laboratories, Intas Pharmaceuticals, Janssen Pharmaceuticals, Lupin, Merck, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Natco Pharma, Nexus Pharmaceuticals, Novo Nordisk, Orchid Chemicals & Pharmaceuticals, Par Pharmaceutical, Parenteral Drugs India, Patheon, Piramal, Roche Holding, Sanofi, Synthon, Teva Pharmaceuticals, Valeant Pharmaceuticals, Zentiva, Zhejiang Huahai Pharmaceutical, and Zydus Cadila.

Commenting on the report, an analyst from the research team said: “One of latest trends in the market is consolidation through vertical integration, alliances, and acquisitions. The major pharmaceutical companies have decreased their operations and R&D budgets, which has led to an increase in demand for outsourced services. Moreover, companies have consolidated their infrastructure in response to a sharp global economic downturn, poor revenue growth prospects, and expensive and inefficient operations. Strategic partnerships between pharmaceutical companies and CMOs have led to the reduction of government spending on manufacturing. The past few years have brought major changes to the pharmaceutical outsourcing services. As more in-house positions have been removed, pharmaceutical vendors are looking for strategic partnerships and 'one-stop' solutions.”

According to the report, one of the primary drivers in the market is high number of US FDA-approved manufacturing facilities in emerging countries. While selecting a partner for outsourcing, pharma companies look for the US FDA-approved plants along with skilled workforce and low operating costs. India, with more than 100 US FDA approved manufacturing facilities, is one of the most preferred locations for outsourcing manufacturing services. According to the research studies published in 2015, Indian suppliers accounted for around 25%-30% of the total drug master files (DMFs) filed with the US FDA. In addition, the implementation of the WTO TRIPS-mandated product patents (January 2005) has led to a rise in outsourcing in the developed markets.

Further, the report states that one major challenge in the market is lack of information integration. One of the greatest challenges faced by most vendors in the pharmaceutical contract manufacturing market is the lack of transparency and information integration in the whole supply chain process. Few medicines, especially vaccines and specialty injections, need fast delivery to ensure their utility. If companies are equipped with a centralized system, they will be able to observe changes in inventory and can order shipments as per requirements. Distribution vehicles or shipments can be redirected to obtain drugs in the required areas. With the right integration of available data from all the stages within the supply chain, companies can keep track of orders and delivery rates. This can effectively cure the delays and disruptions in the pharmaceutical supply chain, making the entire value chain effectively responsive to the unmet medical needs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- Abbott
- Aenova
- Amgen
- Apotex
- Aspen
- AstraZeneca
- Aurobindo Pharma
- BERLIN-CHEMIE
- Baxter
- Biocon
- Biogen
- Boehringer Ingelheim
- Catalent
- Celltrion
- Cipla
- Coherus Biosciences
- Daiichi Sankyo
- Dr. Reddy's Laboratories
- Eli Lilly
- Emcure Pharmaceuticals
- Eurofarma Laboratories
- Fareva
- Gedeon Richter
- Gilead Sciences
- GlaxoSmithKline (GSK),Hospira
- Impax Laboratories
- Intas Pharmaceuticals
- Janssen Pharmaceuticals
- Lonza
- Lupin
- Merck
- Mitsubishi Tanabe Pharma
- Momenta Pharmaceuticals
- Natco Pharma
- Nexus Pharmaceuticals
- Novo Nordisk
- Orchid Chemicals & Pharmaceuticals
- Par Pharmaceutical
- Parenteral Drugs India
- Patheon
- Pfizer CentreOne
- Piramal
- Roche Holding
- Sanofi
- Synthon
- Teva Pharmaceuticals
- Valeant Pharmaceuticals
- Zentiva
- Zhejiang Huahai Pharmaceutical
- Zydus Cadila
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll